Stifel analyst Stephen Gengaro maintained a Buy rating and $86 price target on Core Laboratories following "solid" Q1 results and guidance for the second quarter that supports the 2019 consensus for revenue and EBITDA. In a research note to investors, Gengaro says that though shares are down about 8% following the report, he feels the share weakness -- which could be related to investors' concerns that RD revenue guidance is "too aggressive" -- is overdone. The analyst says that while a higher tax rate likely impacts EPS estimates going forward, he does not see any material changes to consensus expectations for revenue and EBITDA.